Time matters: The prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma-a single-center, retrospective real-world study.
[ABSTRACT] BackgroundPrimary central nervous system lymphoma (PCNSL) is a rare and aggressive malignancy that frequently mimics other central nervous system (CNS) diseases, leading to diagnostic delay
APA
Lehner L, von Baumgarten L, et al. (2026). Time matters: The prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma-a single-center, retrospective real-world study.. Neuro-oncology advances, 8(1), vdaf234. https://doi.org/10.1093/noajnl/vdaf234
MLA
Lehner L, et al.. "Time matters: The prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma-a single-center, retrospective real-world study.." Neuro-oncology advances, vol. 8, no. 1, 2026, pp. vdaf234.
PMID
41696494
Abstract
[ABSTRACT] BackgroundPrimary central nervous system lymphoma (PCNSL) is a rare and aggressive malignancy that frequently mimics other central nervous system (CNS) diseases, leading to diagnostic delays. Given its often nonspecific radiological presentation, PCNSL remains a diagnostic challenge, however early diagnosis and timely initiation of treatment are critical. This study aimed to evaluate diagnostic timelines and their influencing factors, treatment patterns, and their impact on survival in patients with PCNSL.
[METHODS] We retrospectively analyzed 125 patients diagnosed with PCNSL at a single tertiary care referral center between 2008 and 2021. Clinical, radiological, and histopathological data were collected to assess factors influencing diagnostic delay, treatment decisions, and patient outcomes.
[RESULTS] The median age at diagnosis was 68 years (21-89) and median Karnofsky Performance Status (KPS) was 70% (10-100). The median time from initial clinical symptom to histopathologically confirmed diagnosis was 37 days (4-749). The median time from first neuroimaging to confirmed diagnosis was 12 days (2-225). A shorter diagnostic interval (≤ 12 days) was associated with significantly improved overall survival and progression-free survival (PFS) ( < .05). In a multivariate Cox proportional hazards model, predictors of OS were KPS ≥70% ( < .003), preserved renal function (GFR > 60 mL/min, < .027), and MTX-based chemotherapy ( < .001). Further, diagnostic delay (>12 days) emerged as an independent predictor of PFS ( < .024).
[CONCLUSION] Our study underscores the prognostic impact of diagnostic delay in PCNSL. Renal function and KPS emerged as independent OS markers. MTX-based chemotherapy remains the standard of care, with autologous hematopoietic stem cell transplantation providing best survival outcomes in eligible patients.
[METHODS] We retrospectively analyzed 125 patients diagnosed with PCNSL at a single tertiary care referral center between 2008 and 2021. Clinical, radiological, and histopathological data were collected to assess factors influencing diagnostic delay, treatment decisions, and patient outcomes.
[RESULTS] The median age at diagnosis was 68 years (21-89) and median Karnofsky Performance Status (KPS) was 70% (10-100). The median time from initial clinical symptom to histopathologically confirmed diagnosis was 37 days (4-749). The median time from first neuroimaging to confirmed diagnosis was 12 days (2-225). A shorter diagnostic interval (≤ 12 days) was associated with significantly improved overall survival and progression-free survival (PFS) ( < .05). In a multivariate Cox proportional hazards model, predictors of OS were KPS ≥70% ( < .003), preserved renal function (GFR > 60 mL/min, < .027), and MTX-based chemotherapy ( < .001). Further, diagnostic delay (>12 days) emerged as an independent predictor of PFS ( < .024).
[CONCLUSION] Our study underscores the prognostic impact of diagnostic delay in PCNSL. Renal function and KPS emerged as independent OS markers. MTX-based chemotherapy remains the standard of care, with autologous hematopoietic stem cell transplantation providing best survival outcomes in eligible patients.